Signature

PTO/SB/08A (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

erwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control numb Complete if Known Substitute for form 1449/PTO Application Number 10/507.140 Filing Date 19 September 2005 INFORMATION DISCLOSURE First Named Inventor NERI, Dario STATEMENT BY APPLICANT Art Unit 1623 (Use as many sheets as necessary) Examiner Name

		(Use as many sheets as necessar,	v)	Examine	r Name	1		
Sheet	1	of 4		Attorney	Docket Number	PUS-E00	05-105B	フ
	_		U. S. PATE	T DOCUM	ENTE			_
Examiner	Cite No.	Document Number	Publication Date		Name of Patentee	or	Pages, Columns, Lines, Wh	ere
Initials*	No.1	Number-Kind Code ^{2 (Finese)}	MM-DD-YYYY	As	opticant of Cited Docu	ument	Relevant Passages or Relavan Figures Appear	
		^{US-} 5,573,905	11/12/1996	LERNE	Retal.			_
_		US-				$\overline{}$		_
$\overline{}$		US-						_
_		US-						_
	-	us-			-			
		us		+				
		US-				-		_
		us-		-			/	
	_	US-	-	+				
		US-		+				
		US-			/			_
		US-			_/_			_
		US-			_/			
		US-						
		US-		Ж			•	
		US-						
		US-		1				
		US-						
		US-						
			FOREIGN PA	CHT DOCL	MENTO			_
Examinar	Cite	Foreign Patent Document	FUREIGN PA	ublication	Name of Pate	enteror	Pages, Columns, Lines,	т-
Initials*	Cite No.1			Date LDD-YYYY	Applicant of Cited	d Document V	Where Relevant Passages Or Relevant Figures Appear	1
		Country Code ² Number ⁴ Kind Code ² (#	known)			_	Of Relevant Figures Appear	
								_
								\perp
								L
/								
Examiner	_				10	ate		_

CVANIGUES Initial If inference considered, whether or not citation is in conformance with MPEP 603. There his through citation if not in conformance and not considered, include copy of this form with next communication to applicant. *Applicant's artique citation designation number (only "See Kinst Codes of USPFO Phensis Documents at through citation." See Kinst Codes of USPFO Phensis Documents at the Codes of the

Considered

Transition is state-bid.
Transition is extracted.
Transition is extracted by 37 CER 197 and 1.88. This information is required to obtain or retain a benefit by the public which is to fire (and by the public displacement of the control of the cont

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.L./

PTO/S8/08B (09-06) Approved for use through 03/31/2007, OMR 0851-0031

	Un	der the Paperwork Rec	luction A	at of 1995, no persons ar	U.S. Patent re required to respond to a collection	and Trademark Office; U.S. DEPARTMENT OF COMME of information unless it contains a yalid OMB control num	RCE	
/	Subetitu	te for form 1449/PTO			Complete if Known			
1	Jubsiliu	te lor lorin 144a - 10			Application Number	10/507,140		
	INF	ORMATION	DIS	CLOSURE	Filing Date	19 September 2005		
	STA	TEMENT E	BY A	PPLICANT	First Named Inventor	NERI, Dario		
l		(Use as many she		ececcond	Art Unit	1623		
l		1030 as many and	NIS 03 //	occusary)	Examiner Name			
↸	Sheet	2	of	4	Attorney Docket Number	PUS-E005-105B	$\overline{}$	

Examiner Initials*	Cite No.1	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where publisher.	T²
	1	MORGAN et al., Researches on Residual Affinity and Coordination. Part II. Acetylacetones of Selenium and Tellurium, J. Chem. Soc., 1920, p. 1456-65, Vol. 117	
	2	STROBEL et al., Single-site enzymatic cleavage of yeast genomic DNA mediated by triple helix formation, Nature, 1991, p. 172-74, Vol. 350	
	3	CULL et al., Screening for receptor ligands using large libraries of peptides linked to the C terminus of the lac repressor, Proc Natl Acad Sci USA, 1992, p. 1865-69, Vol. 89	
	4	BRENNER et al., Encoded combinatorial chemistry, Proc Natl Acad Sci USA, 1992, p. 5381-83, Vol. 89	
	5	DISTEFANO et al., Energetics of cooperative binding of oligonucleotides with discrete dimerization domains to DNA by triple helix formation,	
		Proc Natl Acad Sci USA, 1993, p. 1179-83, Vol. 90	
	6	WINTER et al., Making antibodies by phage display technology, Annu. Rev. Immunol., 1994, p. 433-55, Vol. 12	
	7	NERI et al., High-affinity Antigen Binding by Chelating Recombinant Antibodies (CRAbs), J. Mol. Biol., 1995, p. 367-73, Vol. 246	
	8	SHUKER et al., Discovering High-Affinity Ligands for Proteins: SAR by NMR Science, 1996, p. 1531-34, Vol. 274	
	_	BODER et al., Yeast surface display for screening combinatorial polypeptide libraries, Nat. Biotechnol., 1997, p. 533-37, Vol. 15	

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

*EXAMINEE: Initial if reference considered, whether or not clustion is in conformance with MPEP 690. Draw line through cluston if not in conformance and not considered, include copy of the form with next communication to applicant.

1. Applicant's unique clustion designation number (optional). 2. Applicant is to prequire the cluster of the Fights in targuage. Threatistics is sittached.

1. Applicant's unique clustion designation number (optional). 2. Applicant is to prequired to obtain or retain a brinefit by the public which is to file (set by the USPTO or protect) in application. Confidentially is governed by 30 U.S. 0. 12 and 37 CFTR 1.14. This collection is estimated to take 2 hours to complete, including submining, preparing, and submitting the completed explication form to the USPTO. Time will vary depending upon the individual case. Any comments on the mount of time by our require to complete the form and/or suggesters for reducing this butter, another but be sent to the Chief Information Officer, 12. Sheft and Trademark Office, P.O. 8box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH, /S.L./

PTO/SB/08B (09-06) Approved for use through 03/31/2007, OMB 0651-0031

	nder the Paperwork Red	uction A	at of 1995, no persons ar	U.S. Pattent and Trademark Office; U.S. DEPARTMENT OF COMMERC re required to respond to a collection of information unless it contains a valid OMB control number Complete if Known		
Substitu	na for form 1449/PTO			Application Number	10/507,140	
INF	ORMATION	DIS	CLOSURE	Filing Date	19 September 2005	
STA	ATEMENT E	BY A	PPLICANT	First Named Inventor	NERI, Dario	
	(Use as many she	ate as n	acessand	Art Unit	1623	
	(Use as many sinc		ocussery)	Examiner Name		
Sheet	3	of	4	Attorney Docket Number	PUS-E005-105B	

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
***************************************		PINI et al., Design and Use of a Phage Display Library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional get,	
		J. Biol. Chem., 1998, p. 21769-76, Vol. 273	
		SCHAFFITZEL et al., Ribosome display: an in vitro method for selection and evolution of antibodies from libraries, J. Immunol. Methods, 1999, p. 119-35, Vol. 231	
	12	BOEHM et al., Structure-based library design: molecular modelling merges with combinatorial chemistry, Current Opinion in Chemical Biology, 2000, p. 283-86, Vol. 4	
	13	DREWS et al., Drug Discovery: A Historical Perspective, Science, 2000, by 1900-94, Vol. 287	
		p. 1900-04, Vol. 287	┝
		BRODY et al., Aptamers as therapeutic and diagnostic agents, J. Biotechnol., 2000, p. 5-13, Vol. 74	
	15	VITI et al., Design and Use of Phage Display Libraries for the Selection of Antibodies and Enzymes, Methods Enzymol., 2000, p. 480-505, Vol. 326	
	16	DESIDERIO et al., A Semi-synthetic Repertoire of Intrinsically Stable Antibody Fragments Derived from a Single-framework Scaffold, J. Mol. Biol., 2001, p. 603-15, Vol. 310	
	17	CHEN et al., Isolation of high-affinity ligand-binding proteins by periplasmic expression with extensive sersening (PEOS), Nat. Biotechnol., 2001, p. 537-42, Vol. 19	
	L.,	GIOVANNONI et al., Isolation of anti-angiogenesis antibodies from a large combinatorial reperfoire by colony filter screening, Nucleic Acids Hes., 2001, p. 1-6, Vol. 29	
		repetiture by colony litter screening, reduced Acids Nes., 2001, p. 1-0, vol. 29	

Examiner	Date
Signature	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Oraw line through citation if not in conformance and not

"ExaMineR: Initial if reference considered, whether or not clustion is in conformance with MePP 090. Given in through clasted in fair to in conformance and not considered, include copy of this form with next communication to applicant.

1 Applicant's unique cational one-signation number (equipment). A popular sit is pleas a clack must have English inspusse 3 Freedilish in sittached.

1 Applicant's unique cational one-signation number (equipment). A popular sit is pleas a clack must have fire fight in signated in sit in the conformance and not conformance and n

PTO/SB/08B (09-06)
Approved for use through 03/31/2007, OMB 0651-0031
U.S. Petent and Trademark Office U.S. DEPARTMENT OF COMMITTEE OF

Under the Paperwork Reduction Act of 1995, no persons an	e required to respond to a collection of information unless it contains a valid OMB control number Complete if Known		
Substitute for form 14437-10	Application Number	10/507,140	
INFORMATION DISCLOSURE	Filing Date	19 September 2005	
STATEMENT BY APPLICANT	First Named Inventor	NERI, Dario	
(Use as many sheets as necessary)	Art Unit	1623	
(Use us many should as necessary)	Examiner Name		
Sheet 4 of 4	Attorney Docket Number	PUS-E005-105B	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
***************************************	19	VARIOUS AUTHORS, Issue of Biopolymers, 2001, p. 121 227, Vol. 56	
100000000000000000000000000000000000000	20	OTTO et al., Dynamic combinatorial chemistry, Drug Discov, Today, 2002, p. 117-25, Vol. 7	
_			
/			

Examiner		Date	02/20/2009
Signature	/Sue Liu/	Considered	02/20/2009

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

"EXAMINEE: Initial if reference considered, whether or not clustion is in conformance with MPEP 009. Draw fine through clusted in fair or incomformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unque cutation designation number (optional). A applicant is to piece a check may be me. English incrues for Frastalistic in situation.

1 Applicant's unque cutation designation number (optional). A applicant is to piece a check may be me. English considered in the properties of the